ĀÜĄņĀŅĀ×

Dr. Andrew Cheng joined Akero in September 2018, as President and Chief Executive Officer. Prior to joining Akero, Andrew served as Gilead Sciencesā€™ Executive Vice President and Chief Medical Officer. During a nearly 20-year tenure at Gilead in positions of increasing responsibility, Andrew was responsible for the clinical development for the HIV program resulting in 11 FDA/EMA approved products. His past responsibilities also included medical affairs and the creation of the development operations department (regulatory affairs, clinical operations, pharmacovigilance, project management, clinical pharmacology, and biometrics), which covered clinical development support in multiple therapeutic areas including oncology, inflammation, respiratory, cardiovascular, HIV, and liver diseases. Andrew serves on the board of directors of Arbutus Biopharma and Vera Therapeutics. He holds a BA in Biology from Johns Hopkins University, and an M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA, and was board certified in internal medicine.